CSPC Pharmaceutical Group (CSPCY) Stock Price, News & Analysis

Company Overview

CSPC Pharmaceutical Group Limited is a China-based pharmaceutical company headquartered in Shijiazhuang, Hebei Province. Established in 1979, the group has grown through organic expansion and strategic acquisitions to become one of the country’s leading manufacturers of active pharmaceutical ingredients (APIs), generic formulations and innovative drug candidates. CSPC is publicly traded in Hong Kong (HKEX: 1093) and maintains American Depositary Receipts on the OTC market (OTCMKTS: CSPCY), reflecting its dual focus on domestic market leadership and international visibility.

The company operates through three primary business segments: bulk pharmaceuticals, finished dosage forms and research-driven products. Its bulk pharmaceuticals division supplies APIs used in anti-infectives, cardiovascular, central nervous system and oncology therapies. The finished dosage group offers a broad portfolio of tablets, capsules, injections and inhalants under both prescription and over-the-counter labels. In recent years, CSPC has placed particular emphasis on advanced biologics, vaccines and novel small-molecule therapies to address unmet medical needs at home and abroad.

CSPC serves a vast distribution network across mainland China and exports key products to over 80 countries and regions in Asia, Europe, Latin America and Africa. The company maintains integrated manufacturing bases in Shijiazhuang, Tianjin, Wangqing and Suzhou, alongside research centres in Beijing and international satellite labs. Its end-to-end supply chain capabilities and regulatory expertise enable timely market launches in regulated markets and faster scale-up of contract manufacturing services.

Under the leadership of Chairman Li Anshan and a senior management team with deep industry experience, CSPC has ramped up R&D investment to more than 10% of annual revenue. Its drug discovery pipeline includes several late-stage clinical candidates spanning oncology, autoimmune disorders and metabolic diseases. By forging partnerships with global pharmaceutical firms and academic institutions, CSPC aims to bolster its innovation platform and secure value-added collaborations to enhance long-term growth.

Key Stats

• Today's Range: C$4.43 to C$4.43
• 50-Day Range: C$3.28 to C$4.43
• 52-Week Range: C$3.26 to C$5.83
• Volume: 210 shs
• Average Volume: 3,329 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CSPCY
• CIK: N/A
• Web: www.cspc.com.hk
• Phone: 86-31-1870-37015
• Fax: N/A
• Employees: 23,500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A